CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleLevered free cash flow is $18.24M, above the global median of $16.24M
- PositionOperating margin is 11.4%, higher than 95% of its Pharmaceutical Retailers peers (median 3.8%)
- Interpretations8 currently firing — 1 · 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.62%Below 5Y avg (4.84%)
Annual Rate
HKD 0.11Paid semi-annual
Payout Ratio
110.0%High
Last Ex-Dividend
Jun 3, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.41BHKD307.37M · vs all stocks (USD)
Trailing P/E
19.50xvs Pharmaceutical Retailers peers
Revenue (TTM)
1.48BCNY189.26M · vs all stocks (USD)
Profit Margin
8.91%vs Pharmaceutical Retailers peers
Beta
-0.1170xvs all stocks
52-Week Change
7.34%vs all stocks
Forward Annual Dividend Yield
4.62%vs all stocks
Market Capitalization
2.41BHKD307.37M · vs all stocks (USD)
Enterprise Value
3.08BHKD392.34M · vs all stocks (USD)
Trailing P/E
19.50xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
2.11xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
2.24xvs Pharmaceutical Retailers peers
Enterprise to Revenue
2.07xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
15.44xvs Pharmaceutical Retailers peers
Profit Margin
8.91%vs Pharmaceutical Retailers peers
Operating Margin
11.38%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
5.96%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
9.73%vs Pharmaceutical Retailers peers
Revenue (TTM)
1.48BCNY189.26M · vs all stocks (USD)
Revenue per Share (TTM)
1.11CNYUpdated Jul 14, 2026Quarterly Revenue Growth
-10.80%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
725.56MCNY92.48M · vs all stocks (USD)
EBITDA (TTM)
192.06MCNY24.48M · vs all stocks (USD)
Net Income (TTM)
132.33MCNY16.87M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.50%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
242.18MCNY30.87M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
143.07MCNY18.24M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1080HKDUpdated Jul 14, 2026Forward Annual Dividend Yield
4.62%vs all stocks
Trailing Annual Dividend Rate
0.1180HKDUpdated Jul 14, 2026Trailing Annual Dividend Yield
5.04%vs all stocks
5-Year Average Dividend Yield
4.84%vs all stocks
Payout Ratio
110.00%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
-4.18MCNYFY2025 · Dec 31, 2025Revenue
1.28BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
656.28MCNYFY2025 · Dec 31, 2025Gross Profit
627.14MCNYFY2025 · Dec 31, 2025Operating Income
145.06MCNY21.50M · vs all stocks (USD)
Pre-tax Income
148.29MCNYFY2025 · Dec 31, 2025Income Tax Expense
43.20MCNYFY2025 · Dec 31, 2025Net Income
105.09MCNYFY2025 · Dec 31, 2025EBIT
150.74MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
192.06MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
486.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.54MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.45MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1000CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.15BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.15BSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
9.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
176.13MCNYFY2025 · Dec 31, 2025Free Cash Flow
151.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
166.61MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
148.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-5.94MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
26.83MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.96MCNYFY2025 · Dec 31, 2025Capital Expenditures
-24.71MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.84MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-33.44MCNYFY2025 · Dec 31, 2025Sale of Investments
5.86MCNYFY2025 · Dec 31, 2025Other Investing Activity
-17.55MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-69.84MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
196.34MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-124.09MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-896.00KCNYFY2025 · Dec 31, 2025Common Dividends Paid
-127.47MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.77MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-59.90MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.16BSharesUpdated Jul 14, 2026Float Shares
215.97MSharesUpdated Jul 14, 2026% Held by Insiders
74.99%vs all stocks
% Held by Institutions
0.43%vs all stocks
Total Cash (MRQ)
195.02MCNY24.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1450CNYUpdated Jul 14, 2026Total Debt (MRQ)
140.44MCNY17.90M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1161xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
3.22xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
1.05CNYUpdated Jul 14, 2026Total Assets
1.49BCNY220.79M · vs all stocks (USD)
Total Current Assets
975.91MCNYFY2025 · Dec 31, 2025Total Liabilities
444.28MCNYFY2025 · Dec 31, 2025Total Non-current Assets
513.59MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
141.15MCNYFY2025 · Dec 31, 2025Total Current Liabilities
303.13MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
166.61MCNYFY2025 · Dec 31, 2025Other Short-term Investments
20.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
279.70MCNYFY2025 · Dec 31, 2025Inventory
297.11MCNYFY2025 · Dec 31, 2025Accounts Payable
167.78MCNYFY2025 · Dec 31, 2025Short-term Debt
58.95MCNYFY2025 · Dec 31, 2025Long-term Debt
62.44MCNYFY2025 · Dec 31, 2025Common Stock (Book)
77.40MCNYFY2025 · Dec 31, 2025Retained Earnings
647.47MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.05BCNY154.93M · vs all stocks (USD)
Treasury Stock
253.77MCNYFY2025 · Dec 31, 202552-Week Low
1.59HKDUpdated Jul 14, 202652-Week High
2.40HKDUpdated Jul 14, 202652-Week Change
7.34%vs all stocks
Beta
-0.1170xvs all stocks
50-Day MA
2.25HKDUpdated Jul 14, 2026200-Day MA
2.20HKDUpdated Jul 14, 2026Avg 10-Day Volume
17.20KSharesUpdated Jul 14, 2026Avg 30-Day Volume
44.70KSharesUpdated Jul 14, 2026Diluted EPS (TTM)
0.1200CNYUpdated Jul 14, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 11.4%, higher than 95% of its Pharmaceutical Retailers peers (median 3.8%)Significant
Operating margin: 0.11Industry median: 0.04Industry P95: 0.08Peers compared: 22.00
Profit margin is 8.9%, higher than 95% of its Pharmaceutical Retailers peers (median 1.6%)Significant
Profit margin: 0.09Industry median: 0.02Industry P95: 0.04Peers compared: 22.00
Return on assets is 6%, higher than 95% of its Pharmaceutical Retailers peers (median 1.9%)Significant
Return on assets: 0.06Industry median: 0.02Industry P95: 0.06Peers compared: 22.00
Current ratio is 3.22×, higher than 95% of its Pharmaceutical Retailers peers (median 1.34×)Significant
Current ratio: 3.22Industry median: 1.34Industry P95: 1.83Peers compared: 22.00
Debt-to-equity is 0.12×, lower than 95% of its Pharmaceutical Retailers peers (median 0.7×)Notable
Debt-to-equity: 0.12Industry median: 0.70Industry P5: 0.19Peers compared: 22.00
Financial Health
Altman Z-Score 5.14: safe zoneNotable
Altman Z-Score: 5.14
High earnings qualityNotable
Earnings Quality Score: 0.72
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Levered free cash flow is $18.24M, above the global median of $16.24MNotable
Levered free cash flow (USD): 18,235,132.199Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Vertu Motors plc
Tier 1FlowUnit ReplicationInterfaceRisk
Giordano International Limited
Tier 1FlowUnit ReplicationRiskInterface
Hunan Dajiaweikang Pharmaceutical Co., Ltd.
Tier 1FlowUnit ReplicationRuleProduction
Zumiez Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
Bintang Oto Global Tbk.
Tier 1FlowUnit ReplicationInterfaceRisk
Retailors Ltd.
Tier 1FlowUnit ReplicationInterfaceRisk
Xebio Holdings Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceAttention
Card Factory plc
Tier 1FlowUnit ReplicationInterfaceProduction
PTG Energy Public Company Limited
Tier 1FlowUnit ReplicationInterfaceProduction
Honeys Holdings Co., Ltd.
Tier 1FlowUnit ReplicationRiskInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
REC Silicon ASA
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedRetained Earnings Heavy With Elevated PayoutLow-Leverage Liquidity Configuration
Winpak Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedRetained Earnings Heavy With Elevated PayoutLow-Leverage Liquidity Configuration
Feng Hsin Steel Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedLiquidity Ratios ElevatedRetained Earnings Heavy With Elevated PayoutLow-Leverage Liquidity Configuration